Monte Carlo bias and variance for the WIPL estimates under different scenarios. The first 4 scenarios belong to Design A and have an average of 1778 (94) placebo (vaccine) cases. Scenario 5 belongs to Design B and has an average of 242 (27) placebo (vaccine) cases. Scenarios 6-8 belong to Design C and has 1254, 94, 25 on placebo original, vaccine, and CPV vaccine arms. All scenarios include in cox model and do not use X(T) value from cases in model fitting unless otherwise noted.
Design . | Scenario . | Feature . | Data . | β0 . | β1 . | β2 . | β3 . |
---|---|---|---|---|---|---|---|
A. . | 1) together . | Bias . | Vaccine . | . | 5e–4 . | –1e–5 . | –0.031 . |
Reference | All | –0.002 | 1.3e–4 | –9e–5 | –0.037 | ||
Variance | Vaccine | 0.161 | 0.331 | 1.707 | |||
All | 1.825 | 0.158 | 0.326 | 0.453 | |||
2) No β3 | Bias | Vaccine | 0.009 | –0.009 | |||
All | –0.005 | 0.014 | –0.014 | ||||
Variance | Vaccine | 0.128 | 0.281 | ||||
All | 1.830 | 0.041 | 0.190 | ||||
3) No β2 and β3 | Bias | Vaccine | 0.002 | ||||
All | –0.034 | 0.009 | |||||
Variance | Vaccine | 0.063 | |||||
All | 0.246 | 0.030 | |||||
4) Add X(T) | Bias | Vaccine | –0.005 | 0.007 | –0.032 | ||
All | –0.007 | –0.003 | 0.005 | –0.036 | |||
Variance | Vaccine | 0.129 | 0.302 | 1.682 | |||
All | 1.774 | 0.125 | 0.290 | 0.396 | |||
B. | 5) together | Bias | Vaccine | –0.020 | 0.012 | –0.108 | |
Few Events | All | –0.014 | –0.022 | 0.015 | –0.111 | ||
Variance | Vaccine | 0.479 | 1.081 | 6.523 | |||
All | 6.510 | 0.458 | 1.055 | 1.518 | |||
C. | 6) together | Bias | Vaccine | –0.002 | 0.002 | –0.013 | |
Placebo Vx | All | –0.009 | –0.002 | 0.003 | –0.023 | ||
Variance | Vaccine | 0.157 | 0.296 | 0.461 | |||
All | 1.434 | 0.157 | 0.296 | 0.430 | |||
7) No β3 | Bias | Vaccine | 0.001 | –0.0003 | |||
All | –0.012 | 0.005 | –0.003 | ||||
Variance | Vaccine | 0.042 | 0.161 | ||||
All | 1.423 | 0.036 | 0.152 | ||||
8) No β2 and β3 | Bias | Vaccine | 0.0002 | ||||
All | –0.012 | 0.002 | |||||
Variance | Vaccine | 0.029 | |||||
All | 0.240 | 0.025 |
Design . | Scenario . | Feature . | Data . | β0 . | β1 . | β2 . | β3 . |
---|---|---|---|---|---|---|---|
A. . | 1) together . | Bias . | Vaccine . | . | 5e–4 . | –1e–5 . | –0.031 . |
Reference | All | –0.002 | 1.3e–4 | –9e–5 | –0.037 | ||
Variance | Vaccine | 0.161 | 0.331 | 1.707 | |||
All | 1.825 | 0.158 | 0.326 | 0.453 | |||
2) No β3 | Bias | Vaccine | 0.009 | –0.009 | |||
All | –0.005 | 0.014 | –0.014 | ||||
Variance | Vaccine | 0.128 | 0.281 | ||||
All | 1.830 | 0.041 | 0.190 | ||||
3) No β2 and β3 | Bias | Vaccine | 0.002 | ||||
All | –0.034 | 0.009 | |||||
Variance | Vaccine | 0.063 | |||||
All | 0.246 | 0.030 | |||||
4) Add X(T) | Bias | Vaccine | –0.005 | 0.007 | –0.032 | ||
All | –0.007 | –0.003 | 0.005 | –0.036 | |||
Variance | Vaccine | 0.129 | 0.302 | 1.682 | |||
All | 1.774 | 0.125 | 0.290 | 0.396 | |||
B. | 5) together | Bias | Vaccine | –0.020 | 0.012 | –0.108 | |
Few Events | All | –0.014 | –0.022 | 0.015 | –0.111 | ||
Variance | Vaccine | 0.479 | 1.081 | 6.523 | |||
All | 6.510 | 0.458 | 1.055 | 1.518 | |||
C. | 6) together | Bias | Vaccine | –0.002 | 0.002 | –0.013 | |
Placebo Vx | All | –0.009 | –0.002 | 0.003 | –0.023 | ||
Variance | Vaccine | 0.157 | 0.296 | 0.461 | |||
All | 1.434 | 0.157 | 0.296 | 0.430 | |||
7) No β3 | Bias | Vaccine | 0.001 | –0.0003 | |||
All | –0.012 | 0.005 | –0.003 | ||||
Variance | Vaccine | 0.042 | 0.161 | ||||
All | 1.423 | 0.036 | 0.152 | ||||
8) No β2 and β3 | Bias | Vaccine | 0.0002 | ||||
All | –0.012 | 0.002 | |||||
Variance | Vaccine | 0.029 | |||||
All | 0.240 | 0.025 |
Monte Carlo bias and variance for the WIPL estimates under different scenarios. The first 4 scenarios belong to Design A and have an average of 1778 (94) placebo (vaccine) cases. Scenario 5 belongs to Design B and has an average of 242 (27) placebo (vaccine) cases. Scenarios 6-8 belong to Design C and has 1254, 94, 25 on placebo original, vaccine, and CPV vaccine arms. All scenarios include in cox model and do not use X(T) value from cases in model fitting unless otherwise noted.
Design . | Scenario . | Feature . | Data . | β0 . | β1 . | β2 . | β3 . |
---|---|---|---|---|---|---|---|
A. . | 1) together . | Bias . | Vaccine . | . | 5e–4 . | –1e–5 . | –0.031 . |
Reference | All | –0.002 | 1.3e–4 | –9e–5 | –0.037 | ||
Variance | Vaccine | 0.161 | 0.331 | 1.707 | |||
All | 1.825 | 0.158 | 0.326 | 0.453 | |||
2) No β3 | Bias | Vaccine | 0.009 | –0.009 | |||
All | –0.005 | 0.014 | –0.014 | ||||
Variance | Vaccine | 0.128 | 0.281 | ||||
All | 1.830 | 0.041 | 0.190 | ||||
3) No β2 and β3 | Bias | Vaccine | 0.002 | ||||
All | –0.034 | 0.009 | |||||
Variance | Vaccine | 0.063 | |||||
All | 0.246 | 0.030 | |||||
4) Add X(T) | Bias | Vaccine | –0.005 | 0.007 | –0.032 | ||
All | –0.007 | –0.003 | 0.005 | –0.036 | |||
Variance | Vaccine | 0.129 | 0.302 | 1.682 | |||
All | 1.774 | 0.125 | 0.290 | 0.396 | |||
B. | 5) together | Bias | Vaccine | –0.020 | 0.012 | –0.108 | |
Few Events | All | –0.014 | –0.022 | 0.015 | –0.111 | ||
Variance | Vaccine | 0.479 | 1.081 | 6.523 | |||
All | 6.510 | 0.458 | 1.055 | 1.518 | |||
C. | 6) together | Bias | Vaccine | –0.002 | 0.002 | –0.013 | |
Placebo Vx | All | –0.009 | –0.002 | 0.003 | –0.023 | ||
Variance | Vaccine | 0.157 | 0.296 | 0.461 | |||
All | 1.434 | 0.157 | 0.296 | 0.430 | |||
7) No β3 | Bias | Vaccine | 0.001 | –0.0003 | |||
All | –0.012 | 0.005 | –0.003 | ||||
Variance | Vaccine | 0.042 | 0.161 | ||||
All | 1.423 | 0.036 | 0.152 | ||||
8) No β2 and β3 | Bias | Vaccine | 0.0002 | ||||
All | –0.012 | 0.002 | |||||
Variance | Vaccine | 0.029 | |||||
All | 0.240 | 0.025 |
Design . | Scenario . | Feature . | Data . | β0 . | β1 . | β2 . | β3 . |
---|---|---|---|---|---|---|---|
A. . | 1) together . | Bias . | Vaccine . | . | 5e–4 . | –1e–5 . | –0.031 . |
Reference | All | –0.002 | 1.3e–4 | –9e–5 | –0.037 | ||
Variance | Vaccine | 0.161 | 0.331 | 1.707 | |||
All | 1.825 | 0.158 | 0.326 | 0.453 | |||
2) No β3 | Bias | Vaccine | 0.009 | –0.009 | |||
All | –0.005 | 0.014 | –0.014 | ||||
Variance | Vaccine | 0.128 | 0.281 | ||||
All | 1.830 | 0.041 | 0.190 | ||||
3) No β2 and β3 | Bias | Vaccine | 0.002 | ||||
All | –0.034 | 0.009 | |||||
Variance | Vaccine | 0.063 | |||||
All | 0.246 | 0.030 | |||||
4) Add X(T) | Bias | Vaccine | –0.005 | 0.007 | –0.032 | ||
All | –0.007 | –0.003 | 0.005 | –0.036 | |||
Variance | Vaccine | 0.129 | 0.302 | 1.682 | |||
All | 1.774 | 0.125 | 0.290 | 0.396 | |||
B. | 5) together | Bias | Vaccine | –0.020 | 0.012 | –0.108 | |
Few Events | All | –0.014 | –0.022 | 0.015 | –0.111 | ||
Variance | Vaccine | 0.479 | 1.081 | 6.523 | |||
All | 6.510 | 0.458 | 1.055 | 1.518 | |||
C. | 6) together | Bias | Vaccine | –0.002 | 0.002 | –0.013 | |
Placebo Vx | All | –0.009 | –0.002 | 0.003 | –0.023 | ||
Variance | Vaccine | 0.157 | 0.296 | 0.461 | |||
All | 1.434 | 0.157 | 0.296 | 0.430 | |||
7) No β3 | Bias | Vaccine | 0.001 | –0.0003 | |||
All | –0.012 | 0.005 | –0.003 | ||||
Variance | Vaccine | 0.042 | 0.161 | ||||
All | 1.423 | 0.036 | 0.152 | ||||
8) No β2 and β3 | Bias | Vaccine | 0.0002 | ||||
All | –0.012 | 0.002 | |||||
Variance | Vaccine | 0.029 | |||||
All | 0.240 | 0.025 |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.